ClosedPublished 26 Sep 2025

Biconomy /
Semnur

Biconomy completes purchase of Semnur shares

Buy side: Biconomy
Buy sideBiconomy
Target: Semnur
TargetSemnur
Scilex Holding Co · 26 Sep 2025Source
Buy side: Biconomy
Buy sideBiconomy
Target: Semnur
TargetSemnur
01 / BuyerBiconomy
02 / TargetSemnur
Source for the buyer and target: Scilex Holding Co

For the buyer and target.

“On September 23, 2025, Scilex Holding Company (the “Company”), Scilex, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Scilex, Inc.” and together with the Company, the “Scilex Sellers”) and, solely with respect to certain registration rights described below, Semnur Pharmaceuticals, Inc., a majority owned subsidiary of the Company (“Semnur”), entered into a Securities Purchase Agreement (“Biconomy Resale SPA”) with Biconomy PTE.LTD (“Biconomy”).”

Published 26 Sep 2025

Open the source
01

What happened

Biconomy purchased 12,500,000 shares of Semnur common stock from Scilex Holding Company and Scilex, Inc. The transaction closed on Sept. 25, 2025. [01]

The shares were sold for $16.00 per share, with payment in Bitcoin. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Scilex Holding Co

Biconomy completes purchase of Semnur shares

This document is the source for the companies, stage, figure and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    “Biconomy completes purchase of Semnur shares Biconomy purchased 12,500,000 shares of Semnur common stock from Scilex Holding Company and Scilex, Inc. The transaction closed on Sept. 25, 2025”

    Open the source
  2. Published by Scilex Holding Co

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.